Skip to content

Monte Rosa Therapeutics, Inc. GLUE Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$75.23M-17.3%
Immunome logo
ImmunomeIMNM
-$53.84M-29.1%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$98.12M-35.8%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$50.67M-3.9%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$105.91M-22.2%
Biohaven logo
BiohavenBHVN

Other financials

Income statement

See full
Revenue$4.2M-95.0%
Operating income-$50.0M-214%
Net income-$44.5M-195%
EPS (diluted)-$0.45-179%

Balance sheet

See full
Cash & equivalents$159.9M+104%
Total debt$39.1M-6.7%
Total equity$521.9M+89.7%
Total assets$736.4M+87.3%

Cash flow

See full
Operating cash flow-$37.4M+17.9%
CapEx$1.9M+17.7%
Free cash flow-$39.2M+16.7%

Valuation

See full
Market cap$1.76B+361%
Enterprise value$1.64B+381%
P/S41×+38.6×

Profitability

See full
Operating margin-345.2%
Net margin-302.6%
FCF margin-45.8%-64.9pp

Returns & leverage

See full
Return on equity-32.6%
Debt / equity0.1×-0.1×
Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Monte Rosa Therapeutics, Inc. (GLUE) reported comprehensive income (loss), net of tax, attributable to parent of -$45.42M in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Monte Rosa Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 196.8% year-over-year, from $46.91M to -$45.42M.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a -19.5% compound annual growth rate (CAGR), from -$74.92M to -$39.1M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on investments and foreign currency translation adjustments. It provides a more holistic view of the company's financial performance by including items that bypass the traditional income statement. This measure is essential for understanding the total economic impact of market-driven fluctuations on the company's net worth.